[
  {
    "ts": null,
    "headline": "Building A $1,000,000 Dividend Portfolio: A Strategy For Growth, Income And Risk Management",
    "summary": "A high net worth dividend portfolio should prioritize capital preservation. Read more about an investment approach that offers diversification and helps generate extra income.",
    "url": "https://finnhub.io/api/news?id=d1598733946b0265a4aa2bc5b8b544b58252b4c9cfb2240b4a67f36ebb3c2056",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740679200,
      "headline": "Building A $1,000,000 Dividend Portfolio: A Strategy For Growth, Income And Risk Management",
      "id": 132901465,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248114016/image_1248114016.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "A high net worth dividend portfolio should prioritize capital preservation. Read more about an investment approach that offers diversification and helps generate extra income.",
      "url": "https://finnhub.io/api/news?id=d1598733946b0265a4aa2bc5b8b544b58252b4c9cfb2240b4a67f36ebb3c2056"
    }
  },
  {
    "ts": null,
    "headline": "Why Novartis Remains A 'Buy' After Beating Expectations Again",
    "summary": "Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read why I maintain my Buy rating on NVS.",
    "url": "https://finnhub.io/api/news?id=b49f962f627f1665d614d75198e399ec2db6f521a9c90fdc497f9d42746bdc43",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740650974,
      "headline": "Why Novartis Remains A 'Buy' After Beating Expectations Again",
      "id": 132900099,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1795327693/image_1795327693.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read why I maintain my Buy rating on NVS.",
      "url": "https://finnhub.io/api/news?id=b49f962f627f1665d614d75198e399ec2db6f521a9c90fdc497f9d42746bdc43"
    }
  },
  {
    "ts": null,
    "headline": "The London Company Large Cap Vs. Russell 1000 Value Q4 2024 Commentary",
    "summary": "The London Company Large Cap portfolio returned 0.8% during the quarter vs. a 2.0% decrease in the Russell 1000 Value Index.",
    "url": "https://finnhub.io/api/news?id=c898a6fcc3906ebd7a813618964800791d55a70b9c6c8c43b8bdce2b332acea3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740645300,
      "headline": "The London Company Large Cap Vs. Russell 1000 Value Q4 2024 Commentary",
      "id": 132899762,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341307278/image_1341307278.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The London Company Large Cap portfolio returned 0.8% during the quarter vs. a 2.0% decrease in the Russell 1000 Value Index.",
      "url": "https://finnhub.io/api/news?id=c898a6fcc3906ebd7a813618964800791d55a70b9c6c8c43b8bdce2b332acea3"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Stock Falls on Report HHS Is Reviewing Bird Flu Vaccine Contract",
    "summary": "Moderna Stock Falls on Report HHS Is Reviewing Bird Flu Vaccine Contract",
    "url": "https://finnhub.io/api/news?id=fe0b04a4cf52268f81e17110039bbea9c0d93aed4a8f8d0b314b971806d75a8c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740645180,
      "headline": "Moderna Stock Falls on Report HHS Is Reviewing Bird Flu Vaccine Contract",
      "id": 132910140,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Moderna Stock Falls on Report HHS Is Reviewing Bird Flu Vaccine Contract",
      "url": "https://finnhub.io/api/news?id=fe0b04a4cf52268f81e17110039bbea9c0d93aed4a8f8d0b314b971806d75a8c"
    }
  },
  {
    "ts": null,
    "headline": "The London Company Large Cap Vs. Russell 1000 Q4 2024 Commentary",
    "summary": "The London Company Large Cap portfolio returned 0.8% during the quarter vs. a 2.8% increase in the Russell 1000 Index.",
    "url": "https://finnhub.io/api/news?id=55fc6d4534a1b75fa56f1cf69295e1c5dbac8d167a3deee6bb8f80e27e2c2b5d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740628800,
      "headline": "The London Company Large Cap Vs. Russell 1000 Q4 2024 Commentary",
      "id": 132898062,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367307651/image_1367307651.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The London Company Large Cap portfolio returned 0.8% during the quarter vs. a 2.8% increase in the Russell 1000 Index.",
      "url": "https://finnhub.io/api/news?id=55fc6d4534a1b75fa56f1cf69295e1c5dbac8d167a3deee6bb8f80e27e2c2b5d"
    }
  }
]